Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2011
08/02/2011CA2605972C Treatment or prevention of ovarian hyperstimulation syndrome (ohss) using a dopamine agonist
08/02/2011CA2583259C Aromatic ring fused pyrimidine derivative
08/02/2011CA2565053C Biodegradable intraocular implants containing prostamides
08/02/2011CA2542105C Compounds and compositions as protein kinase inhibitors
08/02/2011CA2538752C Quinazoline derivatives
08/02/2011CA2537978C Substituted quinolines as protein tyrosine kinase enzyme inhibitors
08/02/2011CA2525835C Toremifene crystallization method
08/02/2011CA2523859C Methods and devices for the sustained release of multiple drugs
08/02/2011CA2518885C Pharmaceutical composition for intracellular acidification with cis-urocanic
08/02/2011CA2507262C Pharmaceutical composition containing bakuchiol for treating female osteoporosis
08/02/2011CA2505067C Methods of screening for compounds that inhibit the biosynthesis of gpi in malaria parasites
08/02/2011CA2503196C Compositions that treat or inhibit pathological conditions associated with inflammatory response
08/02/2011CA2498735C Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
08/02/2011CA2496538C Boronic ester and acid compounds, synthesis and uses
08/02/2011CA2489723C Novel aryl-{4-halo-4-[heteroaryl-methylamino)-methyl]-piperidin-1-yl}-methanone derivatives, methods for production and use thereof as medicaments
08/02/2011CA2489209C New derivatives of arylsulfonamides and use thereof in therapy
08/02/2011CA2488242C Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same
08/02/2011CA2486678C Non-viral gene delivery system
08/02/2011CA2479109C Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
08/02/2011CA2475780C 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use to prepare drugs for treatment of immunological diseases
08/02/2011CA2474043C Heterocyclic compounds which are active as inhibitors of beta lactamases
08/02/2011CA2471577C Chemical compounds
08/02/2011CA2470956C 1-alkyl-1-azoniabicyclo[2.2.2]octane carbamate derivatives and their use as muscarinic receptor antagonists
08/02/2011CA2463709C N-substituted pyrrolidin derivatives as dipeptidyl peptidase iv inhibitors
08/02/2011CA2459493C New pharmaceutical compositions for inhalation
08/02/2011CA2458325C Nutritional composition for controlling blood sugar level
08/02/2011CA2458025C Novel 4-aminofuropyrimidines and the use thereof
08/02/2011CA2449298C A coated nicotine-containing chewing gum, manufacture and use thereof
08/02/2011CA2447010C Substituted 4h-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
08/02/2011CA2442870C Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide hiv protease inhibitors
08/02/2011CA2434063C Substituted quinolines for the treatment of protozoan and retrovirus co-infections
08/02/2011CA2427964C Method and preparations having effect against allergic symptoms
08/02/2011CA2423999C Compositions and medical devices utilizing bioabsorbable liquid polymers
08/02/2011CA2419420C Thioflavin derivatives for use in antemortem diagnosis of alzheimer's disease and in vivo imaging and prevention of amyloid deposition
08/02/2011CA2419285C New uses for amino acid anticonvulsants
08/02/2011CA2417255C Medicament comprising amrubicin and an anti-her2 antibody for treating breast cancer
08/02/2011CA2414211C Hyaluronic acid oligosaccharide fractions and drugs containing the same
08/02/2011CA2407309C Dna sequences encoding dystrophin minigenes and methods of use thereof
08/02/2011CA2405349C Oxazolidinone derivatives with antibiotic activity
08/02/2011CA2395593C Azaindoles
08/02/2011CA2370187C Treatment of neoplasms with viruses
08/02/2011CA2368824C Rapid dehydration of proteins
08/02/2011CA2366723C Fatty acid-anticancer conjugates and uses thereof
08/02/2011CA2364451C Agent for treatment of arthritic disease
08/02/2011CA2330829C Methods for treating a neurological disease by determining bche genotype
08/02/2011CA2323207C Food products having enhanced cocoa polyphenol content and processes for producing same
08/01/2011CA2719442A1 Method of treatment of egfr inhibitor toxicity
07/2011
07/29/2011CA2730634A1 Shunt delivery of curcumin
07/28/2011WO2011091446A1 Chemical compounds
07/28/2011WO2011091436A1 Quantitative analysis of vitamin d3, vitamin d2, and metabolites thereof
07/28/2011WO2011091413A1 Method and dosage form to confirm compliant use of a bioactive agent
07/28/2011WO2011091410A1 Trpv4 antagonists
07/28/2011WO2011091407A1 Trpv4 antagonists
07/28/2011WO2011091401A2 Treatment of immune disorders using kainate receptor antagonists
07/28/2011WO2011091390A2 Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
07/28/2011WO2011091299A1 Composition for perinatal and neonatal stroke
07/28/2011WO2011091276A1 Therapeutic substituted chlorocyclopentanols
07/28/2011WO2011091225A2 Alpha-2 adrenergic agonist having long duration of intraocular pressure-lowering effect
07/28/2011WO2011091213A2 Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof
07/28/2011WO2011091209A1 Small molecule modifiers of microrna mir-122
07/28/2011WO2011091204A1 5-(1h-pyrazol-5-yl)thiazole-based compounds for the treatment of diseases and disorders of the eye
07/28/2011WO2011091167A2 Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases
07/28/2011WO2011091164A1 Oral dosage forms having a high loading of a tranexamic acid prodrug
07/28/2011WO2011091153A1 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
07/28/2011WO2011091152A1 Inhibitors of hepatitis c virus infection
07/28/2011WO2011091142A2 Crystalline and amorphous forms of olanzapine pamoate
07/28/2011WO2011091131A2 Eslicarbazepine acetate and its polymorphs
07/28/2011WO2011091122A1 Methods for internally controlling or treating equine bot larvae
07/28/2011WO2011091084A2 Stabilized proteases for use in skin care
07/28/2011WO2011091033A1 Modulation of neurogenesis by ppar agents
07/28/2011WO2011091019A1 Methods and compositions for treating and preventing parenteral nutrition associated liver disease
07/28/2011WO2011090977A1 Formation and uses of europium complexes
07/28/2011WO2011090947A2 Methods for the diagnosis and treatment of parkinson's disease
07/28/2011WO2011090929A1 Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
07/28/2011WO2011090926A1 Nutritional formulas containing synbiotics
07/28/2011WO2011090923A1 Modified release formulation and methods of use
07/28/2011WO2011090922A1 Nutritional compensation for western-type diet
07/28/2011WO2011090911A1 Amino heteroaryl compounds as beta-secretase modulators and methods of use
07/28/2011WO2011090885A2 Enhanced anti-microbial pdt
07/28/2011WO2011090760A1 Heteroaryl compounds and uses thereof
07/28/2011WO2011090741A2 TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
07/28/2011WO2011090740A2 Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
07/28/2011WO2011090738A2 Type ii raf kinase inhibitors
07/28/2011WO2011090725A2 Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
07/28/2011WO2011090724A2 Gastroretentive solid oral dosage forms with lipid-based low-density excipient
07/28/2011WO2011090694A1 Orally administrable film dosage forms containing ondansetron
07/28/2011WO2011090676A1 Compositions including pyruvate for companion animals and methods of use thereof
07/28/2011WO2011090669A1 Methods for treating pain
07/28/2011WO2011090666A2 Methods for treating autism
07/28/2011WO2011090404A1 Composition for preparing iso-osmotic therapeutic-prophylactic baths and body wraps
07/28/2011WO2011090345A2 Novel antibiotic composition comprising flufenamic acid as an active ingredient
07/28/2011WO2011090317A2 Imidazopyrazinone derivatives with apoptosis inducing activity on cells
07/28/2011WO2011090316A2 Novel pyrazinone derivatives having an apoptosis-inducing activity, and pharmaceutical compositions comprising same
07/28/2011WO2011090307A2 Sirna having antiviral activity against both enterovirus 70 and coxsackievirus a24, and pharmaceutical composition for treating and preventing acute hemorrhagic conjunctivitis containing same
07/28/2011WO2011090283A2 Composition containing inhibitors of the expression or activity of sh3rf2 for preventing or treating cancer
07/28/2011WO2011090265A2 Composition containing cinchonine as an active ingredient for preventing and treating obesity, dyslipidemia, fatty liver, or insulin resistance syndrome
07/28/2011WO2011090095A1 Heterocyclic compound having azole group
07/28/2011WO2011090062A1 Piperazine compound having a pgds inhibitory effect
07/28/2011WO2011090005A1 Pharmaceutical preparation for colon cancer, and treatment method
07/28/2011WO2011089995A1 Hydroxamic acid derivative and hdac8 inhibitor using same